News – Page 99 – Endpoints News

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

8 months ago

Adcomm says Intercept's rare liver disease drug should not get full approval

8 months ago

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

8 months ago

After a huge IPO and acquisition, Zymergen caps off bankruptcy with $30M SEC penalty

8 months ago

Post-Hoc: Big promises built Moderna. They might also be its undoing

8 months ago

Atea's polymerase inhibitor fails in late-stage Covid-19 treatment trial

8 months ago

Aurinia restructures board, bringing in Kevin Tang and keeping CEO

8 months ago

FDA approves subcutaneous Ocrevus, broadening access to Roche and Genentech blockbuster

8 months ago

WHO pre-qualifies Bavarian Nordic’s vaccine as first mpox shot

8 months ago

Online stimulant prescriptions soared during Covid pandemic, study finds

8 months ago

Valneva raises about €61M; Immuneering details new Phase 2a data

8 months ago

Doug Williams returns with a ‘FIT’ bet on CAR-Ts; Biogen appoints Mene Pangalos to board

8 months ago

Oncternal stops cancer trials and begins search for future business options

8 months ago

Neurocrine culls Phase 2 neuropsych med after failing to validate earlier data

8 months ago

Bicara, Zenas and MBX rekindle IPO market with rare Friday tripleheader

8 months ago

Corrected: Roche’s Tecentriq scores first US approval for subcutaneous PD-L1

8 months ago

Seres' microbiome therapy reduces infections in stem cell transplant patients, but next steps are unclear

8 months ago

FDA revisits new structure for drug review documents, aiming to better explain its decisions

8 months ago

Avadel's narcolepsy drug Lumryz misses PDUFA date, still under review at FDA

8 months ago

FDA should embrace new ways of evaluating rare disease drugs, report argues

8 months ago

Australian RNA manufacturer launches; Forge Biologics’ CEO steps down

8 months ago

Debiopharm, ITM ink up to €300M licensing deal for cancer treatment

8 months ago

GSK’s mRNA flu shot is heading to Phase 3; Summit’s $235M offering

8 months ago

Fulcrum's Phase 3 for old GSK drug fails, stock sinks

8 months ago

First page Previous page 96 97 9899100 101 102 Next page Last page